Aurinia Pharmaceuticals Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $44.84M, a 3640.20% increase year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $610.00K, a 71.83% increase year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.63M, a 593.19% increase year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.20M, a 213.05% increase year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.60M, a 124.17% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $2.05M, a 32.66% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $3.05M, a 484.84% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $521.00K, a 97.78% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $44.84M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $610.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $4.60M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.63M 10-Q · filed 2025-11-04 | $4.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.20M 10-Q · filed 2026-08-06 | $3.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $355.00K 10-Q · filed 2026-08-06 | $2.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $235.00K 10-Q · filed 2025-11-04 | $669.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $383.00K 10-Q · filed 2025-11-04 | $1.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $28.00K 10-Q · filed 2025-11-04 | $1.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.15M 10-Q · filed 2024-11-07 | $3.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $234.00K 10-Q · filed 2024-08-01 | $1.87M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-02 | $1.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $521.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $8.59M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $117.00K 10-Q · filed 2023-08-03 | $17.66M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $405.00K 10-Q · filed 2023-05-04 | $18.83M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $23.42M 10-K · filed 2024-02-15 |
| 2021-09-30 | $9.07M 10-Q · filed 2022-11-03 | $16.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.28M 10-Q · filed 2022-08-04 | $9.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $5.00M 10-Q · filed 2022-05-10 | $8.72M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $6.64M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.52M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $955.00K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $2.92M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $13.75M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $943.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |